Hemab Therapeutics (NASDAQ:COAG) Stock Rating Upgraded by Zacks Research

Hemab Therapeutics (NASDAQ:COAG) was upgraded by equities researchers at Zacks Research to a “hold” rating in a note issued to investors on Wednesday,Zacks.com reports.

Several other equities research analysts have also issued reports on COAG. Wedbush initiated coverage on shares of Hemab Therapeutics in a research note on Tuesday. They issued an “outperform” rating and a $42.00 price target on the stock. Jefferies Financial Group started coverage on Hemab Therapeutics in a report on Tuesday. They issued a “buy” rating and a $39.00 price objective for the company. Wall Street Zen raised Hemab Therapeutics to a “hold” rating in a research report on Saturday, May 9th. The Goldman Sachs Group assumed coverage on Hemab Therapeutics in a report on Tuesday. They set a “buy” rating and a $36.00 target price on the stock. Finally, Evercore started coverage on Hemab Therapeutics in a research report on Tuesday. They set an “outperform” rating and a $50.00 price target for the company. Four research analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $41.75.

Hemab Therapeutics Stock Performance

Shares of COAG opened at $28.00 on Wednesday. Hemab Therapeutics has a twelve month low of $23.00 and a twelve month high of $36.61.

Hemab Therapeutics (NASDAQ:COAG) last announced its quarterly earnings data on Thursday, May 21st. The company reported ($23.98) EPS for the quarter.

Insider Buying and Selling at Hemab Therapeutics

In other news, Director Ra Capital Management, L.P. acquired 2,675,000 shares of the stock in a transaction on Monday, May 4th. The shares were purchased at an average price of $18.00 per share, for a total transaction of $48,150,000.00. Following the transaction, the director directly owned 6,149,096 shares of the company’s stock, valued at approximately $110,683,728. This represents a 77.00% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Insiders purchased a total of 2,902,872 shares of company stock worth $53,769,784 in the last 90 days.

Hemab Therapeutics Company Profile

Hemab Therapeutics is a clinical-stage biotechnology company focused on developing novel therapies for people with serious bleeding and thrombotic disorders. The company’s research is centered on treatments designed to address diseases of the blood and coagulation system, with the goal of improving outcomes for patients who may not be adequately served by existing options.

Hemab’s pipeline includes drug candidates aimed at rare hematologic conditions, including factor XI-related approaches and other programs in inherited bleeding disorders.